An early-stage trial, conducted in the United States, will test the vaccine in healthy adults aged 65- 85.
Pfizer Inc. said on Monday it had tested a flu vaccine based on messenger RNA in the first patient to be used in COVID-19 shots made by US drugmaker BioNTech.
An early-stage trial, conducted in the United States, will test the vaccine in healthy adults aged 65- 85.
“The COVID-19 pandemic has allowed us to provide vast scientific opportunities for mRNA. Influenza remains an area where we need vaccines,” said Katherine Jansen, head of vaccine research and development at Pfizer.
The study will test the vaccine’s safety and immune responses compared to an FDA-approved influenza vaccine.
.